Arcus Biosciences Inc’s latest rating changes from various analysts

Arcus Biosciences Inc’s filing revealed that its President Jaen Juan C. unloaded Company’s shares for reported $0.14 million on Jan 02. In the deal valued at $20.09 per share,6,975 shares were sold. As a result of this transaction, Jaen Juan C. now holds 1,215,265 shares worth roughly $19.1 million.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Then, Goeltz II Robert C. sold 2,004 shares, generating $40,080 in total proceeds. Upon selling the shares at $20.00, the Chief Financial Officer now owns 51,831 shares.

Before that, Jarrett Jennifer sold 21,521 shares. Arcus Biosciences Inc shares valued at $382,213 were divested by the Chief Operating Officer at a price of $17.76 per share. As a result of the transaction, Jarrett Jennifer now holds 258,878 shares, worth roughly $4.07 million.

BofA Securities initiated its Arcus Biosciences Inc [RCUS] rating to a Neutral in a research note published on , November 18, 2022; the price target was $33.

Price Performance Review of RCUS

On Tuesday, Arcus Biosciences Inc [NYSE:RCUS] saw its stock jump 2.75% to $15.72. Over the last five days, the stock has gained 1.81%. Arcus Biosciences Inc shares have fallen nearly -17.70% since the year began. Nevertheless, the stocks have fallen -32.04% over the past one year. While a 52-week high of $25.47 was reached on 01/02/24, a 52-week low of $12.95 was recorded on 01/29/24. SMA at 50 days reached $16.53, while 200 days put it at $18.25. A total of 2.11 million shares were traded, compared to the trading of 0.29 million shares in the previous session.

Levels Of Support And Resistance For RCUS Stock

The 24-hour chart illustrates a support level at 15.01, which if violated will result in even more drops to 14.29. On the upside, there is a resistance level at 16.60. A further resistance level may holdings at 17.49. The Relative Strength Index (RSI) on the 14-day chart is 42.43, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.73, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.67%. Stochastics %K at 13.77% indicates the stock is a buying.

How much short interest is there in Arcus Biosciences Inc?

A steep rise in short interest was recorded in Arcus Biosciences Inc stocks on Jan 11, 2024, growing by 0.38 million shares to a total of 7.15 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2023 was 6.77 million shares. There was a rise of 5.31%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 16.05% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.63.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular